Advances in Mucosal Adjuvants for Influenza Vaccines
Viral Immunology · 2026
DOI: 10.1177/08828245251413233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viral Immunology, 2026. Verfasst von Genzhu Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmacy, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China. Hauptthemen laut MEDLINE: Influenza Vaccines, Adjuvants, Immunologic, Immunity, Mucosal, Influenza, Human. Die Arbeit nennt 118 Literaturangaben. Gefördert von: “Pioneerâ€? and “Leading Gooseâ€?R&D Program of Zhejiang, Science Foundation of Zhejiang Sci-Tech University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Vaccination is an effective way to prevent influenza virus infection. Currently, intramuscular vaccines are the most commonly used and can provide strong humoral immunity, but they may not induce the mucosal immune response well. A variety of pathogens gain access to the host via the respiratory tract, and the mucosa serves as the initial line of defense against bacterial invasions. Therefore, developing mucosal vaccines is a valuable strategy for preventing respiratory infectious diseases. The mucosal barrier hinders antigen delivery and immune activation, making efficient mucosal adjuvants crucial for vaccine advancement, though their use faces several obstacles. The main challenges faced by mucosal adjuvants are mucosal tolerance, delivery efficiency, and immune response balance. Future mucosal adjuvants will continue to focus on multitarget synergistic design and combination adjuvant application. The safety and efficacy of future influenza vaccines are contingent upon the judicious selection of suitable mucosal adjuvants. The creation of next-generation influenza vaccines will be made easier as our knowledge of adjuvants grows. In this review, we summarize the current progress and applications of mucosal adjuvants for influenza vaccines, with implications for the development of novel influenza vaccines and vaccines against other infectious diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biopharmacy, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
- Department of Biology, College of Life Sciences, China Jiliang University, Hangzhou, China.
ORCID-Profile: Huapeng Feng
Förderung
- “Pioneer� and “Leading Goose�R&D Program of Zhejiang
- Science Foundation of Zhejiang Sci-Tech University
- National Natural Science Foundation of China
- Zhejiang Province Science and Technology Cooperation Project of “Three Rural and Nine Parties�
- Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Wang, G., Wu, L., Wu, X., Tao, Y., Li, S., Li, C., Yao, Y., Xu, S., Xia, H., Li, M., Shu, J., He, Y., & Feng, H. (2026). Advances in Mucosal Adjuvants for Influenza Vaccines. Viral Immunology. https://doi.org/10.1177/08828245251413233
Vancouver
Wang G, Wu L, Wu X, Tao Y, Li S, Li C, et al. Advances in Mucosal Adjuvants for Influenza Vaccines. Viral Immunology. 2026. doi:10.1177/08828245251413233
BibTeX
@article{Wang2026,
author = {Wang, Genzhu and Wu, Li and Wu, Xing and Tao, Yingying and Li, Shaozhen and Li, Chengying and Yao, Yao and Xu, Shijia and Xia, Hongyi and Li, Menghao and Shu, Jianhong and He, Yulong and Feng, Huapeng},
title = {Advances in Mucosal Adjuvants for Influenza Vaccines},
journal = {Viral Immunology},
year = {2026},
doi = {10.1177/08828245251413233}
}
EUVIMED